Polish biotech Intelliseq raises €4M investment from Vinci Fund
Summary
Approximately 350 million people around the world are affected by rare genetic diseases, with many remaining undiagnosed for years due to the limitations of traditional lab methods. Founded in 2014 by scientists Klaudia Szklarczyk-Smolana, Marcin Piechota, Micha Korostyski, and Sawomir Goda, Intelliseq develops bioinformatics tools that streamline automated DNA analysis and enhance genetic diagnostics. Intelliseq, alongside the Metrodora Institute and its UK partner PrecisionLife, has created tools to evaluate predispositions to chronic fatigue syndrome and long COVID. By integrating with the DNAnexus ecosystem, Intelliseq offers advanced genomic analysis tools and reports on somatic cancers and hereditary diseases to prominent healthcare systems. We see a growing demand for scalable bioinformatics solutions, especially in the U.S., where the molecular diagnostics market is expanding rapidly," says Klaudia Szklarczyk-Smolana, PhD, CEO of Intelliseq.The fresh funds will propel the companys entry into the US and advance the creation of cutting-edge algorithms for predicting disease risks.